[{"orgOrder":0,"company":"Mural Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2016","type":"Inapplicable","leadProduct":"ALKS 4230","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Mural Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mural Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Mural Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2019","type":"Inapplicable","leadProduct":"ALKS 4230","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Mural Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mural Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Mural Oncology \/ Undisclosed"},{"orgOrder":0,"company":"Clovis Oncology","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Lucitanib","moa":"||Vascular endothelial growth factor receptor | Fibroblast growth factor receptor 1 | Fibroblast growth factor receptor 2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clovis Oncology","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clovis Oncology \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clovis Oncology \/ Undisclosed"}]

Find Clinical Drug Pipeline Developments & Deals for ALKS 4230

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : Findings explore the pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of Rubraca and lucitanib alone and in combination with other agents in preclinical models and simulated patient populations.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          June 17, 2020

                          Lead Product(s) : Lucitanib,ALKS 4230

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ALKS4230 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 04, 2019

                          Lead Product(s) : ALKS 4230

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          OTS 2025
                          Not Confirmed
                          OTS 2025
                          Not Confirmed

                          Details : ALKS4230 is a Protein drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 14, 2016

                          Lead Product(s) : ALKS 4230

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank